331. Idiopathic multicentric castleman disease
30 clinical trials,   44 drugs   (DrugBank: 23 drugs),   30 drug target genes,   148 drug target pathways

Searched query = "Idiopathic multicentric castleman disease", "Castleman disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03864419
(ClinicalTrials.gov)
October 24, 20191/3/2019Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in UgandaA Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With Local Standard-of-Care Chemotherapy for the Treatment of Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma or as Monotherapy for Kaposi Sarcoma Herpesvirus Associated Multicentric Castleman Disease in Pediatrics and Adults in UgandaBurkitt Lymphoma;KSHV-associated Multicentric Castleman Disease;Diffuse Large B-Cell LymphomaBiological: Rituximab or Rituximab Hyaluronidase Human;Drug: Cyclophosphamide;Drug: Vincristine;Drug: Methotrexate;Drug: Doxorubicin;Drug: Doxorubicin Hydrochloride;Drug: Prednisone;Drug: EtoposideFred Hutchinson Cancer Research CenterNational Cancer Institute (NCI)Recruiting2 YearsN/AAll40Phase 1Uganda;United States
2NCT03043105
(ClinicalTrials.gov)
January 1, 201731/1/2017TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot TrialThalidomide, Cyclophosphamide and Prednisone in Newly Diagnosed Multicentric Castleman's Disease: a Prospective, Single-center, Single-arm, Phase-II Pilot TrialMulticentric Castleman DiseaseDrug: Thalidomide, cyclophosphamide and prednisonePeking Union Medical College HospitalNULLActive, not recruiting18 YearsN/AAll25Phase 2China
3NCT02228512
(ClinicalTrials.gov)
August 15, 201427/8/2014Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated LymphomasPhase I/II Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas (Primary Effusion Lymphoma and Large Cell Lymphoma Arising in KSHV-Associated Multicentric Castleman Disease)Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease;Primary Effusion LymphomaDrug: Pomalidomide;Drug: Rituximab;Drug: Prednisone;Drug: Etoposide;Drug: Doxorubicin;Drug: Vincristine;Drug: CyclophosphamideNational Cancer Institute (NCI)NULLWithdrawn18 Years99 YearsAll0Phase 1;Phase 2United States
4NCT00092222
(ClinicalTrials.gov)
October 28, 200421/9/2004Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease ActivityTargeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease With Laboratory and Clinical Correlates of Disease ActivityLymphoproliferative Disorder;HHV-8;Malignancy;HIVDrug: Etoposide;Drug: Interferon-alpha;Drug: Rituximab;Drug: Zidovudine;Drug: Liposomal Doxorubicin;Drug: Bortezomib;Drug: Valganciclovir;Drug: Doxorubicin;Drug: Vincristine;Drug: Cyclophosphamide;Drug: Filgrastim (G-CSF);Drug: Prednisone;Drug: Sirolimus;Other: Observation OnlyNational Cancer Institute (NCI)NULLRecruiting12 YearsN/AAll72Phase 2United States